You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Development of PAR2 Pepducins for the Treatment of Atopic Dermatitis
SBC: OASIS PHARMACEUTICALS, LLC Topic: NIAMSDESCRIPTION provided by applicant Atopic dermatitis AD or severe eczema is a very common life long skin disease with of adults in the US requiring systemic therapy Clinical manifestations of AD include multiple inflamed lesions erosions accompanied by lichenification thick leathery skin fibrotic papules and severely dry skin with increased susceptibility to infection A major uncont ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Investigation of a nanoparticle albumin-bound mTOR inhibitor, nab-rapamycin for t
SBC: AADI, LLC Topic: 102DESCRIPTION provided by applicant In it is estimated that there will be new bladder cancer cases in the United States resulting in deaths Most cases present with nonmuscle invasive bladder cancer NMIBC Intravesical bacillus Calmette Guerin BCG which elicits a nonspecific local immune response is considered the standard first line treatment However ...
STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health -
Development and testing of a behavioral activation mobile therapy for elevated depressive symptoms
SBC: MOUNTAINPASS TECHNOLOGY LLC Topic: 104DESCRIPTION provided by applicant Approximately of the population experiences elevated depressive symptoms Kubik et al Despite recent research suggesting that overall population mortality would be reduced by if the effects of subthreshold depression could be blocked completely the majority of individuals with elevated depressive symptoms never receive evidence based treat ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Novel Activin A Antagonists for Treatment of Osteoporosis
SBC: ABREOS BIOSCIENCES, INC. Topic: NIAMSDESCRIPTION provided by applicant Bone loss and fragility from osteoporosis afflict more than million people worldwide including at least million Americans Current osteoporosis treatments are significantly deficient most fail to reverse bone loss and or have adverse effects that prohibit their long term use New therapeutic approaches are urgently needed Recently the TGF family li ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Recyclable Magnetic Co C Hybrid ROMP Reagents Scavengers and Ligands
SBC: MATERIA, INC. Topic: 300DESCRIPTION provided by applicant This Fast Track Small Business Technology Transfer study between Materia Inc in Pasadena CA and the University of Kansas intends to build upon successes of our current Phase II Fast Track STTR grant R GM which ends on March Preliminary results serve as a solid foundation for this Fast Track submission entitled andquot Development of Re ...
STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health -
Peptide Based Therapy for Lung Fibrosis
SBC: Novici Biotech LLC Topic: NHLBIDESCRIPTION provided by applicant Fibroproliferative illnesses leading to organ fibrosis and failure are responsible for approximately of deaths in developed countries whether idiopathic triggered by environmental factors infections or genetics organ fibrosis results in significant morbidity and mortality Organ fibrosis is responsible for health care costs exceeding $ billion year ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Real-Time Oxygen Monitoring for Tissue Health: Peripheral Artery Disease Application
SBC: PROFUSA, INC. Topic: NHLBIDESCRIPTION provided by applicant Continuous biochemical monitoring has the power to change currently accepted standards of care shifting the emphasis from treating illness to maintaining health Point in time snapshots of a patientandapos s health can miss critical fluctuations or early warning signs that might warrant early interventions or changes in disease treatment and management PROFUS ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Lowering the Cost of Imaging for Retinal Microvasculature in Diabetic Patients
SBC: AEON IMAGING LLC Topic: WDESCRIPTION provided by applicant Recently we found extensive remodeling of the microvasculature of the retina occurring in some diabetic patients much earlier than expected This provides the potential for novel biomarkers However the equipment is too expensive for most clinics and small practices These early retinal microvascular changes cannot be seen with routine clinical examination o ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
A Visual Assessment System for Retinal Function/Drug Discovery
SBC: AFASCI INC Topic: NDESCRIPTION provided by applicant Preclinical evaluation of treatment strategies for retinal neurodegenerative diseases is highly dependent on mouse models Classical methods to assess the visual function of animals such as electroretinogram ERG which measures electrical responses in the retina do not address connections between the eye and brain or visual perception by the visual system ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Effectiveness of VBP15, a dissociative steroidal analogue, on inflammation in a mouse model of arthritis
SBC: ReveraGen BioPharma, Inc. Topic: NIAMSDESCRIPTION provided by applicant Glucocorticoids GCandapos s such as prednisolone are used frequently to induce remission and treat rheumatoid arthritis RA Despite effectiveness many GC mediated detrimental side effects including osteoporosis and muscle atrophy limit long term chronic treatment of RA patients In addition juvenile arthritis patients suffer from th side effect of signi ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health